Table 5.

Prevalence of fluctuations and dyskinesia according to gender at the start of treatment with safinamide and during the follow-up.

Motor complications	Gender	Baseline	4 months	8 months	12 months
Any fluctuations	Female	93.6%	78.2%	74.6%	71.8%
	Male	91.6%	71.3%	69.2%	66.3%
Wearing-off	Female	76.5%	58.5%	56.7%	56.0%
	Male	73.5%	52.8%	52.3%	51.7%
Dyskinesia	Female	48.8%	44.6%	39.9%	35.1%
	Male	33.2%	28.3%	26.6%	23.3%
Early morning fluctuations	Female	25.7%	15.1%	16.8%	14.4%
	Male	21.5%	13.0%	13.5%	13.1%
Unpredictable fluctuations	Female	17.5%	11.0%	11.1%	11.0%
	Male	16.2%	11.2%	11.2%	9.2%
Delayed ON	Female	11.9%	9.8%	8.5%	8.1%
	Male	11.0%	7.2%	7.8%	8.6%

Percentages (%) were computed by column.